
aug pm et
summari lead global supplier health care product well world largest
manufactur privat label over-the-counter pharmaceut infant formula
price-to-earnings oper ep
risk assess reflect view
rel inexpens over-the-counter product larg
unaffect econom cycl chang govern
reimburs compani also strong
competit advantag largest maker store
past perform indic futur perform reli upon
analysi prepar equiti analyst
aug pm stock trade
presid mr rhrhoff former
ceo germany-bas gerresheim ag
global pharmaceut supplier look
sale exclud tysabri
see sale consum healthcar
america consum healthcar
intern prescript
pharmaceut see continu price
basi point partli due increas
 sale market cost
august announc wil
separ prescript pharmaceut unit
spin-off sale merger effort
focu consum busi
prescript pharmaceut unit account
sale highest
oper margin compar
consum unit
march sold tysabri royalti
right royalti pharma plu
potenti payment
royalti earn meet
specifi threshold think price
low end note declin tysabri sale
competit multipl sclerosi
market tysabri gener royalti
see uncertainti follow tysabri
deal on-going strateg review signific
manag chang anticip
continu volatil challeng
howev uwe rohrhoff
instal ceo ronald winowiecki cfo
anticip improv stabil
manag team although think
valu tysabri deal somewhat
low end believ use fund
pay debt financi
flexibl encourag deal
reach amazon manufactur basic
over-the-counter product current product
unsur much sale
gener still earli stage
risk recommend target price
includ slow sale due increas
competit pressur challeng new
eros inabl get fair valu
potenti sale merger prescript
target base
peer forward ep
estim see continu on-going
challeng encourag
strategi simplifi portfolio focu
nov ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview lead global health care supplier develop manufactur
distribut over-the-count over-the-counter prescript pharmaceut nutrit product activ
pharmaceut ingredi api consum product world largest manufactur
over-the-counter pharmaceut product privat label store brand market store brand product contain
activ ingredi advertis brand lower cost consum store brand
retail sell product store anoth chosen brand name
consum product compris broad line over-the-counter store brand product compar qualiti efficaci
advertis brand product cost retail store brand product significantli lower
compar nation advertis brand name product retail therefor price store
brand product compet nation brand product yet realiz greater profit margin store
major consum product categori includ analges cough/cold/allergy/sinu medic
gastrointestin smoke cessat item exampl store brand analges acetaminophen
activ ingredi brand tylenol consum product also includ broad rang household
product includ cosmet toiletri deterg bar soap sold carelin neca
gener busi focus develop manufactur sale gener prescript
pharmaceut primarili market manufactur oper base israel
spray liquid suspens solut well nasal spray oral liquid transderm product
compani also manufactur market brand prescript drug licens firm
pharmaceut medic diagnost product import israel exclus
agreement primarili chemagi busi manufactur complex chemic
activ pharmaceut ingredi api use world-wide gener drug industri certain
ingredi also use pharmaceut product api facil israel germani
china nutrit compris infant formula product infant toddler food oral electrolyt
solut product well vitamin miner dietari supplement product
compani sell product chain drug store wholesal distributor hospit system
group purchas organ well retail drug supermarket mass merchandis chain
also collabor agreement
cobrek pharmaceut
impact major develop march sold tysabri royalti right royalti pharma
bilion plu potenti payment royalti earn meet
specifi threshold think price low end note declin tysabri sale
competit multipl sclerosi market tysabri gener million million royalti
gener busi augment juli acquisit paddock laboratori
million cash februari purchas million
expans veterinari product facilit acquisit sergeant pet
million septemb velcera million april decemb acquir
corpor billion subsequ re-loc corpor headquart ireland
believ lower corpor tax rate ireland enabl compani save million tax
annual march acquir omega pharma nv billion omega develop
over-the-count product annual sale billion
financi trend sale aid primarili acquisit rose
billion billion repres three-year compound annual growth
rate compound-annual-growth-rate follow omega acquisit sale rose sale adjust
ep declin partli due sale tysabri royalti stream right
march encount slow sale consum healthcar unit
chairman board
senior director
global oper
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli under-valued
bullish sinc juli technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
e-estim na-not avail nm-not meaning nr-not rank ur-und review prior fiscal year end jun
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook pharmaceut
sub-industri next month neutral
although issu high drug price remain
overhang industri believ
impact lessen believ
trump administr push
regulatori chang forc drug price
may trump administr releas
drug price blueprint american patient
first view offer littl polici
regulatori chang rein escal drug
price rather see consolid
amongst largest drug purchas
health insur pharmaci benefit manag
hospit effort increas buy
firm announc rais
price drug year
signific portion firm organ
follow june drug price
innov work group draft
execut order aim tackl high drug
price draft focus reduc regul
method increas competit lower
intellectu properti right scale back
discount given hospit serv lower
incom patient import note mani
individu serv work group
former pharmaceut execut
like cfra view put forward
separ believ top-lin pressur
patent expir mani top-sel drug
bottom anticip modest
organ sale increas low-singl digit
also see expand sale new
innov drug therapi margin
improv accru cost restructur
merger synergi
see afford act
continu neg affect industri
margin see benefit includ improv
sale demand signific expans
insur popul accord
depart human servic
insur sinc law enact
howev repeal individu mandat
compon requir
peopl health insur pay fine
includ tax cut job act
pass decemb repeal
mandat effect januari
expect fewer insur patient
despit advers effect patent
expir pressur high drug price
still think long-term prospect
remain one widest-margin
industri prospect enhanc
demograph growth elderli
account industri sale
new drug discoveri number
new molecular entiti approv rebound
approv number
approv sinc
record approv follow robust
approv
approv
 pharmaceut index
increas versu rise
 composit index year date
juli pharmaceut
declin vs rise
base index
five-year market price perform aug
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
peer forward ep estim ep vs
ahead estim follow signific improv
intern consum healthcar unit pro forma sale rose
encourag improv oper continu portfolio
restructur divest under-perform asset includ announc sale
isra api unit howev still anticip volatil intern unit
rais ep estim /jeffrey loo cfa
et cfra keep hold opinion share compani plc
keep target in-lin peer
ep estim lower ep
refil account recent sold tysabri royalti
financi asset rather intang asset file
soon practic guid sale ep
view transit year tysabri sale
continu weak intern consum health care unit
improv america unit brand pharmaceut /jeffrey loo
announc restat fy
transit period soon practic restat base
determin auditor ernst young
tysabri royalti stream record financi asset rather
intang asset also identifi defer tax asset adjust
result reduct goodwil off-set reduct defer
tax liabil separ provid preliminari sale
guid sale exclud tysabri rang /jeffrey
analyst research note compani news
et cfra lower opinion share compani plc
hold buy lower target price
below-p forward ep estim see
challeng consum busi particularli anim health unit
price eros prescript pharmaceut unit ep vs
estim lower ep estim
ep estim sale fell consum
fx benefit rose prescript pharmaceut sale fell
separ announc separ prescript
pharmaceut unit spin-off sale merger
prescript pharmaceut unit account sale
highest oper margin unit compar
consum healthcar unit /jeffrey loo cfa
buy hold keep target
line peer ep estim ep vs
ahead view consum healthcar america sale rose
consum healthcar sale aid fx benefit
rose howev prescript pharmaceut sale
expect partli due price eros suppli disrupt new
product scopolamin launch believ
re-launch scopolamin along anticip launch
gener proair although cautiou prescript pharmaceut
unit encourag improv consum healthcar unit
america oper margin improv bp
unit saw oper margin improv bp share lower
today trade ep estim peer
attract valu view /jeffrey loo cfa
keep target line peer
ep estim near mid-point five-year rang
set ep vs ahead
estim forma sale modestli segment show posit
growth encourag result appear restructur
includ sale asset gener posit result expect new
ceo uwe roehrhoff evalu strateg plan provid flat modest
sale growth wide ep rang /jeffrey loo cfa
share significantli reschedul
earn releas slate today state need addit time
complet final incom tax review procedur relat reconcili
non-cash item new date given howev provid preliminari
sale line forecast state gener net sale
segment guidanc also state oper cash flow
compani guidanc base metric believ earn
line forecast /jeffrey loo cfa
et cfra keep hold opinion share compani plc
rais target peer
forward ep estim ep vs
ahead estim rais ep estim
consum healthcar improv oversea
pro-forma sale prescript sale rose oper
margin improv across three segment well encourag
result restructur includ sale certain asset
note highli competit market price pressur /jeffrey loo cfa
et cfra keep hold opinion share compani plc
keep target price in-lin
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
